L ista de publicaciones realizadas en colaboración con la Unidad de Investigación de la AEDV:

Biobadaderm y Psonet:

  • Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchon-Romero I, Carrascosa JM, Ferran M et al. Br J Dermatol 2017; 176: 797-9.
  • Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Perez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, Herrera-Ceballos E et al. J Eur Acad Dermatol Venereol 2017; 31: 1021-8.
  • Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D et al. Br J Dermatol 2017; 176: 643-9.
  • Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G et al. J Am Acad Dermatol 2017; 76: 299-308 e16.
  • Psoriasis, Metabolic Syndrome, and Systematic Reviews. Descalzo MA. Actas Dermosifiliogr 2017; 108: 323.
  • Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Davila-Seijo P, Garcia-Doval I, Naldi L, Cazzaniga S, Augustin M, Rustenbach SJ et al. Acta Derm Venereol 2017; 97: 516-8.
  • Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis. Davila-Seijo P, Garcia-Doval I. Actas Dermosifiliogr 2017; 108: 697-8.
  • Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis. Davila-Seijo P, Garcia-Doval I. Actas Dermosifiliogr 2017; 108: 3-5.
  • Registries as a real-world cohort studies that are useful and necessary in the pyramid of evidence. Davila-Seijo P, Descalzo MA. Br J Dermatol 2017.
  • Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F et al. J Invest Dermatol 2017; 137: 313-21.
  • Clinical Research in Dermatology in Spain. Davila Seijo P. Actas Dermosifiliogr 2017.
  • Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. Belinchon I, Ramos JM, Carretero G, Ferrandiz C, Rivera R, Dauden E et al. J Eur Acad Dermatol Venereol 2017.
  • Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. Garcia-Doval I, Perez-Zafrilla B, Ferrandiz C, Carretero G, Dauden E, de la Cueva P et al. J Dermatolog Treat 2016; 27: 203-9.
  • Management of biologic therapy in moderate to severe psoriasis in surgical patients: Data from the Spanish Biobadaderm Registry. Galiano Mejias S, Carretero G, Ferrandiz C, Vanaclocha F, Dauden E, Gomez-Garcia FJ et al. Actas Dermosifiliogr 2016.
  • A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature. Echeverria-Garcia B, Nuno-Gonzalez A, Dauden E, Vanaclocha F, Torrado R, Belinchon I et al. Actas Dermosifiliogr 2016.
  • Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. Davila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ et al. J Eur Acad Dermatol Venereol 2016; 30: 1942-50.
  • Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Sanz-Bueno J, Vanaclocha F, Garcia-Doval I, Torrado R, Carretero G, Dauden E et al. Actas Dermosifiliogr 2015; 106: 477-82.
  • Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ et al. J Eur Acad Dermatol Venereol 2015; 29: 858-64.
  • Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastian F, Gomez-Garcia FJ, Herrera-Ceballos E et al. J Eur Acad Dermatol Venereol 2015; 29: 156-63.
  • Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E et al. Actas Dermosifiliogr 2015; 106: 638-43.
  • Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. Carrascosa JM, Garcia-Doval I, Perez-Zafrilla B, Carretero G, Vanaclocha F, Dauden E et al. J Dermatolog Treat 2015; 26: 502-6.
  • Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Dauden E et al. J Eur Acad Dermatol Venereol 2014; 28: 907-14.
  • Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. Sanchez-Moya AI, Garcia-Doval I, Carretero G, Sanchez-Carazo J, Ferrandiz C, Herrera Ceballos E et al. J Eur Acad Dermatol Venereol 2013; 27: 1366-74.
  • Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C et al. Br J Dermatol 2013; 169: 710-4.
  • Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL et al. Arch Dermatol 2012; 148: 463-70.
  • [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Rivera R, Garcia-Doval I, Carretero G, Dauden E, Sanchez-Carazo J, Ferrandiz C et al. Actas Dermosifiliogr 2011; 102: 132-41.

Registro de cirugía de Mohs (REGESMOHS):

  • Characterization of Surgical Procedures in the Spanish Mohs Surgery Registry (REGESMOHS) for 2013-2015. de Eusebio Murillo E, Martin Fuentes A, Ruiz-Salas V, Garces JR, Minano Medrano R, Lopez-Estebaranz JL et al. Actas Dermosifiliogr 2017.
  • Mohs micrographic surgery in the elderly. Comparison of tumours, surgery, and first-year follow-up in patients younger and older than 80 years-old in REGESMOHS. Camarero-Mulas C, Delgado Jimenez Y, Sanmartin-Jimenez O, Garces JR, Rodriguez-Prieto MA, Alonso-Alonso T et al. J Eur Acad Dermatol Venereol 2017.
  • Description of Patients Undergoing Mohs Surgery in Spain: Initial Report on Data From the Spanish Registry of Mohs Surgery (REGESMOHS). Ruiz-Salas V, Garces JR, Minano Medrano R, Alonso-Alonso T, Rodriguez-Prieto MA, Lopez-Estebaranz JL et al. Actas Dermosifiliogr 2015; 106: 562-8.
  • Census of Centers That Perform Mohs' Micrographic Surgery in Spain and Description of Their Activity: A Feasibility Study for the Mohs' Micrographic Surgery Registry of the Foundation of the Spanish Academy of Dermatology and Venereology. Alonso-Alonso T, Redondo-Bellon P, Sanmartin-Jimenez O, de Eusebio-Murillo E, Garcia-Doval I, Rodriguez-Prieto MA. Actas Dermosifiliogr 2015; 106: 764-6.

Mapa de Investigación:

  • A Map of Clinical Dermatology Research Centers in Spain: Results of the MaIND Study. Molina-Leyva A, Descalzo MA, Garcia-Doval I. Actas Dermosifiliogr 2017.

Otros proyectos:

  • Methyl aminolevulinate photodynamic therapy for onychomycosis: a multicentre, randomized, controlled clinical trial. Gilaberte Y, Robres MP, Frias MP, Garcia-Doval I, Rezusta A, Aspiroz C. J Eur Acad Dermatol Venereol 2017; 31: 347-54.
  • Fragmented Health Care Delivery in Ichthyosis. Hernandez-Martin A, Davila'Seijo P, Soria de Francisco JM, Arroyo-Manzanal MI, Garcia-Doval I. Actas Dermosifiliogr 2015; 106: 514-5.
  • Prioritization of therapy uncertainties in congenital ichthyosis: results from a Priority Setting Partnership. Hernandez-Martin A, Davila-Seijo P, de Lucas R, Baselga E, Redondo P, Martin-Santiago A et al. Br J Dermatol 2015; 173: 1280-3.
  • Research unit of the Spanish Academy of Dermatology and Venerology Foundation. Garcia-Doval I. Actas Dermosifiliogr 2015; 106: 346-9.
  • Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians. Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow E, Rajan C, Garcia-Doval I. J Am Acad Dermatol 2014; 71: 1008-11.
  • Prevalence of dystrophic epidermolysis bullosa in Spain: a population-based study using the 3-source capture-recapture method. Evidence of a need for improvement in care. Hernandez-Martin A, Aranegui B, Escamez MJ, de Lucas R, Vicente A, Rodriguez-Diaz E et al. Actas Dermosifiliogr 2013; 104: 890-6.
  • Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders. Davila-Seijo P, Hernandez-Martin A, Morcillo-Makow E, de Lucas R, Dominguez E, Romero N et al. Orphanet J Rare Dis 2013; 8: 61.
  • Prevalence of autosomal recessive congenital ichthyosis: a population-based study using the capture-recapture method in Spain. Hernandez-Martin A, Garcia-Doval I, Aranegui B, de Unamuno P, Rodriguez-Pazos L, Gonzalez-Ensenat MA et al. J Am Acad Dermatol 2012; 67: 240-4.

Revisiones Sistemáticas:

  • Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-Garcia C, Rodriguez-Pazos L, Pastushenko I et al. Actas Dermosifiliogr 2016; 107: 318-28.
  • Phototherapy in atopic dermatitis: a systematic review of the literature. Perez-Ferriols A, Aranegui B, Pujol-Montcusi JA, Martin-Gorgojo A, Campos-Dominguez M, Feltes RA et al. Actas Dermosifiliogr 2015; 106: 387-401.
  • A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. Hernandez-Martin A, Aranegui B, Martin-Santiago A, Garcia-Doval I. J Am Acad Dermatol 2013; 69: 544-9 e8.

Publicaciones resultantes de asesorías:

  • Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Gonzalez-Llorente N, Del Olmo-Benito I, Munoz-Ollero N, Descalzo MA, Garcia-Doval I, Torrelo A. Pediatr Dermatol 2017; 34: 554-8.
  • Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis. Esteves T, Aparicio G, Garcia-Patos V. BMC Pulm Med 2016; 16: 165.